CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Chemomab Therapeutics Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026
$1.17−0.09 (-7.51%)
Close on Oct 19, 2026
- Market cap
- $749.09M
- P/E (TTM)
- 65.0
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.1%
0M of 575M shares
Institutional holders
13
1 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
2 buys · 2 sales
Net bought $13.73K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| HBM Healthcare Investments (Cayman) Ltd. | 80,971,680 | 12.50% | 13D (active) amendment | Sep 7, 2026 |
| Touchstone Global Investments Pty Ltd | 377,814 | 5.20% | 13G (passive) | Aug 7, 2026 |
| Morgan Stanley | 32,282,680 | 8.40% | 13G (passive) | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CMMB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 95,311 | 0.02% | $154.40K | +31,129 | 0.00% |
| ADAR1 Capital Management, LLC | 80,000 | 0.01% | $129.60K | – | 0.01% |
| Kestra Private Wealth Services, LLC | 61,710 | 0.01% | $99.97K | – | 0.00% |
| Ikarian Capital, LLC | 51,793 | 0.01% | $83.90K | – | 0.01% |
| Rhumbline Advisers | 30,529 | 0.01% | $49.46K | +12,163 | 0.00% |
| XTX Topco Ltd | 15,987 | 0.00% | $25.90K | −2,642 | 0.00% |
| Philadelphia Investment Partners, LLC | 15,000 | 0.00% | $24.30K | +6,800 | 0.02% |
| Lido Advisors, LLC | 14,341 | 0.00% | $23.23K | New | 0.00% |
| Bnp Paribas Arbitrage, Snc | 6,805 | 0.00% | $11.02K | −1,620 | 0.00% |
| GAMMA Investing LLC | 4,740 | 0.00% | $7.68K | −2,839 | 0.00% |
| Morgan Stanley | 3,575 | 0.00% | $5.79K | −1,000 | 0.00% |
| SBI Securities Co., Ltd. | 34 | 0.00% | $55 | +6 | 0.00% |
| Caitong International Asset Management Co., Ltd | 8 | 0.00% | $13 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 13 | 0M | 0.1% | 1 / 4 | 4 / 3 | 0M | 0M |
| Q1 2026 | 15 | 0M | 0.1% | 4 / 6 | 3 / 3 | 0M | 0M |
| Q4 2025 | 14 | 0M | 0.1% | 6 / 4 | 3 / 2 | 0M | 0M |
| Q3 2025 | 10 | 0M | 0.1% | 10 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| George Adi Mor | Chief Executive Officer, Director | 68,809 | 0.01% | Jun 1, 2026 |
| Sigal Fatal | Chief Financial Officer | 12,500 | 0.00% | Apr 10, 2026 |
| John Lawler | Chief Development Officer | 10,148 | 0.00% | Apr 10, 2026 |
| Neil Harris Cohen | Director | 33,000 | 0.01% | Sep 1, 2026 |
| Gwen A. Melincoff | Director | – | – | Jun 3, 2026 |
| Alan Charles Moses | Director | – | – | Apr 10, 2026 |
| Nissim Darvish | Director | 300 | 0.00% | Apr 10, 2026 |
| Claude Nicaise | Director | – | – | Mar 31, 2026 |
| Jill M. Quigley | Director | – | – | Mar 31, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Neil Harris Cohen Director | Aug 28, 2026 | Sale | −1,000 | $2.80 | $2.80K | 33,000 |
| Neil Harris Cohen Director | Aug 27, 2026 | Sale | −1,304 | $2.85 | $3.72K | 34,000 |
| George Adi Mor Chief Executive Officer, Director | May 29, 2026 | Other | −18,750 | – | – | 18,750 |
| George Adi Mor Chief Executive Officer, Director | May 29, 2026 | Other | −31,712 | – | – | 31,712 |
| George Adi Mor Chief Executive Officer, Director | May 29, 2026 | Buy | −4,926 | $2.08 | $10.25K | 139,131 |
| George Adi Mor Chief Executive Officer, Director | May 29, 2026 | Buy | −4,878 | $2.05 | $10.00K | 134,205 |
| Israel BioFund GP Limited Partnership OrbiMed 10% owner | Jan 3, 2023 | Sale | −266,376 | $3.34 | $889.70K | 2,311,798 |
| Israel BioFund GP Limited Partnership OrbiMed 10% owner | Jan 3, 2023 | Sale | −70,524 | $4.51 | $318.06K | 2,241,274 |
| George Adi Mor Chief Scientific Officer, Director | Jan 3, 2023 | Sale(10b5-1 plan) | −7,700 | $5.03 | $38.73K | 317,075 |
| George Adi Mor Chief Scientific Officer, Director | Jan 3, 2023 | Sale(10b5-1 plan) | −6,100 | $5.03 | $30.68K | 251,147 |
| Neil Harris Cohen Director | Nov 16, 2022 | Sale | −2,409 | $2.00 | $4.82K | 10,000 |
| George Adi Mor Chief Scientific Officer, Director | Nov 16, 2022 | Sale | −257,248 | $2.08 | $535.08K | 257,247 |
| George Adi Mor Chief Scientific Officer, Director | Nov 16, 2022 | Sale | −324,775 | $2.08 | $675.53K | 324,775 |
| Joel Michael Maryles Director | May 24, 2022 | Buy | +33 | $2.76 | $91 | 1,433 |
| Joel Michael Maryles Director | May 24, 2022 | Buy | +400 | $2.89 | $1.16K | 1,400 |
| Neil Harris Cohen Director | May 18, 2022 | Buy | +2,000 | $3.19 | $6.38K | 12,409 |
| Joel Michael Maryles Director | Mar 18, 2022 | Buy | +500 | $4.32 | $2.16K | 500 |
| Joel Michael Maryles Director | Mar 18, 2022 | Buy | +500 | $4.36 | $2.18K | 1,000 |
| Donald Marvin Executive VP, CFO & COO | Mar 16, 2022 | Buy | +250 | $3.25 | $813 | 2,000 |
| Donald Marvin Executive VP, CFO & COO | Mar 16, 2022 | Buy | +250 | $3.30 | $825 | 1,750 |
| Donald Marvin Executive VP, CFO & COO | Mar 14, 2022 | Buy | +250 | $3.98 | $995 | 500 |
| Donald Marvin Executive VP, CFO & COO | Mar 14, 2022 | Buy | +250 | $4.00 | $1.00K | 250 |
| Donald Marvin Executive VP, CFO & COO | Mar 14, 2022 | Buy | +250 | $4.20 | $1.05K | 1,500 |
| Donald Marvin Executive VP, CFO & COO | Mar 14, 2022 | Buy | +250 | $4.10 | $1.03K | 1,250 |
| Donald Marvin Executive VP, CFO & COO | Mar 14, 2022 | Buy | +250 | $3.90 | $975 | 1,000 |
| Neil Harris Cohen Director | Mar 14, 2022 | Buy | +2,000 | $4.20 | $8.40K | 6,409 |
| Neil Harris Cohen Director | Mar 14, 2022 | Buy | +2,000 | $4.30 | $8.60K | 8,409 |
| Neil Harris Cohen Director | Mar 14, 2022 | Buy | +2,000 | $4.56 | $9.12K | 10,409 |
| Dale R. Pfost Chief Executive Officer, Director | Mar 14, 2022 | Buy | +1,800 | $3.98 | $7.16K | 1,800 |
| Dale R. Pfost Chief Executive Officer, Director | Mar 14, 2022 | Buy | +700 | $3.97 | $2.78K | 2,500 |
| Nissim Darvish Director | Mar 11, 2022 | Buy | +1,200 | $4.28 | $5.14K | 1,200 |
| Neil Harris Cohen Director | Dec 6, 2021 | Buy | +2,000 | $7.43 | $14.86K | 4,409 |
| Neil Harris Cohen Director | Mar 16, 2021 | Buy | +2,409 | $41.51 | $100.00K | 2,409 |
| Peter Thiel 10% owner | Mar 16, 2021 | Buy | +230,536 | – | – | 1,108,509 |
| Israel GP Ltd. OrbiMed 10% owner | Mar 16, 2021 | Award | +288,170 | $17.35 | $5.00M | 2,578,174 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Israel Partners Limited Partnership OrbiMed Owner | Sep 12, 2024 | 500,000 | $1.02M | Sep 12, 2024 | Merger |